Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial Tumors

Epithelial Tumors ◽

Programmed Death ◽

Prognostic and clinicopathological roles of programmed death‐ligand 1 ( PD‐L1 ) expression in thymic epithelial tumors: A meta‐analysis

Thoracic Cancer ◽

10.1111/1759-7714.13590 ◽

2020 ◽

Vol 11 (11) ◽

pp. 3086-3098

Author(s):

Hyun Min Koh ◽

Bo Gun Jang ◽

Hyun Ju Lee ◽

Chang Lim Hyun

Keyword(s):

Meta Analysis ◽

Epithelial Tumors ◽

P1.14-11 The Expression Pattern of Programmed Death-Ligand 1 According to the Pathological Type of Malignant Thymic Epithelial Tumors

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.08.913 ◽

2018 ◽

Vol 13 (10) ◽

pp. S604

Author(s):

S. Ishihara ◽

S. Okada ◽

H. Ogi ◽

Y. Kodama ◽

K. Itoh ◽

...

Keyword(s):

Expression Pattern ◽

Epithelial Tumors ◽

Pathological Type ◽

Programmed Death-ligand 1 (PD-L1) Expression in Thymic Epithelial Tumors

Applied Immunohistochemistry & Molecular Morphology ◽

10.1097/pai.0000000000000699 ◽

2020 ◽

Vol 28 (1) ◽

pp. 1-9 ◽

Cited By ~ 4

Author(s):

Judit Bedekovics ◽

Livia Beke ◽

Attila Mokanszki ◽

Szabolcs Szilagyi ◽

Gabor Mehes

Keyword(s):

Epithelial Tumors ◽

Safety and clinical activity of anti-programmed death-ligand 1 (PD-L1) antibody (ab) avelumab (MSB0010718C) in advanced thymic epithelial tumors (TETs).

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.e20106 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. e20106-e20106 ◽

Cited By ~ 4

Author(s):

Arun Rajan ◽

Christopher Ryan Heery ◽

Susan Perry ◽

Corrine Keen ◽

Andrew L Mammen ◽

...

Keyword(s):

Clinical Activity ◽

Epithelial Tumors ◽

Expression of programmed death 1 (PD-1) and its ligand (PD-L1) in thymic epithelial tumors: Impact on treatment efficacy and alteration in expression after chemotherapy

Lung Cancer ◽

10.1016/j.lungcan.2016.05.007 ◽

2016 ◽

Vol 99 ◽

pp. 4-10 ◽

Cited By ~ 36

Author(s):

Yuki Katsuya ◽

Hidehito Horinouchi ◽

Tetsuhiko Asao ◽

Shinsuke Kitahara ◽

Yasushi Goto ◽

...

Keyword(s):

Treatment Efficacy ◽

Epithelial Tumors ◽

Programmed Death ◽

Programmed Death 1 ◽

Impact On Treatment

PROGRAMMED DEATH-1 (PD-1), PROGRAMMED DEATH-LIGAND 1 (PD-L1) EXPRESSION IN UTERINE GRADE 3 ENDOMETRIOID ADENOCANCER

10.26226/morressier.597eedbed462b80296ca1075 ◽

2017 ◽

Author(s):

Kucukgoz Gulec Umran

Keyword(s):

Programmed Death ◽

Programmed Death 1 ◽

Grade 3

Antagonizing programmed death-1 and programmed death ligand-1 as a therapeutic approach for gastric cancer

Therapeutic Advances in Gastroenterology ◽

10.1177/1756283x16658251 ◽

2016 ◽

Vol 9 (6) ◽

pp. 853-860 ◽

Cited By ~ 5

Author(s):

Xiaojun Liu ◽

Zhongxia Yang ◽

Olivier Latchoumanin ◽

Liang Qiao

Keyword(s):

Gastric Cancer ◽

Therapeutic Approach ◽

Programmed Death ◽

Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti–programmed death-1 and anti–programmed death ligand 1 trials

European Journal of Cancer ◽

10.1016/j.ejca.2018.10.011 ◽

2019 ◽

Vol 106 ◽

pp. 1-11 ◽

Cited By ~ 10

Author(s):

Run-Cong Nie ◽

Fo-Ping Chen ◽

Shu-Qiang Yuan ◽

Ying-Shan Luo ◽

Shi Chen ◽

...

Keyword(s):

Overall Survival ◽

Disease Control ◽

Objective Response ◽

Progression Free Survival ◽

End Points ◽

Free Survival ◽

Programmed Death ◽

Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma

Chinese Journal of Cancer ◽

10.1186/s40880-017-0226-3 ◽

2017 ◽

Vol 36 (1) ◽

Cited By ~ 20

Author(s):

Yuan Gao ◽

Su Li ◽

Dazhi Xu ◽

Shangxiang Chen ◽

Yuchen Cai ◽

...

Keyword(s):

T Cell ◽

Lymph Nodes ◽

Cell Density ◽

Prognostic Value ◽

Cd8 T Cell ◽

Primary Tumors ◽

Programmed Death ◽

Programmed Death 1 ◽

Stage T1

Evaluation of programmed death 1 (PD-1) and programmed death ligand-1 (PD-L1) as tumor biomarkers an in patients with head and neck squamous cell carcinoma

Journal of Medical and Dental Practice ◽

10.18044/medinform.202072.1198 ◽

2020 ◽

Vol 7 (2) ◽

pp. 1198-1202

Author(s):

Elitsa Deliverska ◽

Payam Forghani ◽

Sadeta Parusheva

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Neck Squamous Cell Carcinoma ◽

Tumor Biomarkers ◽

Programmed Death ◽